Oral administration of thiol-reducing agents mitigates gut barrier disintegrity and bacterial lipopolysaccharide translocation in a rat model of biliary obstruction [0.03%]
硫醇还原剂的口服给药可通过减轻胆道梗阻大鼠模型中的肠道屏障功能障碍而减少细菌脂多糖的移位
Mohammad Mehdi Ommati,Omid Farshad,Hossein Niknahad et al.
Mohammad Mehdi Ommati et al.
It has been well documented that cirrhosis is associated with the intestinal injury. Intestinal injury in cirrhosis could lead to bacterial lipopolysaccharide (LPS) translocation to the systemic circulation. It has been found that high plas...
Joshua Moody,Chalen Yang,Jessica Sedinkin et al.
Joshua Moody et al.
Atherosclerosis involves interactions between inflammation system and dyslipidemia. MCPIP1 (Monocyte Chemotactic Protein induced Protein-1) is induced by proinflammatory molecules and serves as a negative feedback loop in regulating inflamm...
Poppy O Smith,Peiqin Jin,Khondaker Miraz Rahman
Poppy O Smith
Repurposing regulatory agency approved drugs and investigational compounds with known safety profiles can significantly fast track the drug development timeline over de novo drug discovery, with lower investment requirements and improved at...
Potential value of pharmacological agents acting on toll-like receptor (TLR) 7 and/or TLR8 in COVID-19 [0.03%]
作用于Toll样受体（TLR）7和/或TLR8的药物在COVID-19中的潜在价值
Amani E Khalifa,Asser I Ghoneim
Amani E Khalifa
The COVID-19 pandemic is an ongoing global pandemic of coronavirus disease 2019 as an atypical type of viral pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Many potential pharmacotherapies are currently be...
Potential inhibitors of SARS-CoV-2 (COVID 19) spike protein of the delta and delta plus variant: In silico studies of medicinal plants of North-East India [0.03%]
东北印度药用植物中潜在的SARS-CoV-2（COVID 19）刺突蛋白(delta和delta plus变异体)抑制剂：计算机研究
Peter Solo,M Arockia Doss
Peter Solo
Phytochemicals of 38 Medicinal plants of North-East India, with anti-viral, anti-oxidant or anti-bacterial properties were screened for properties of drug likeness. 231 phytochemicals were screened with LIPINSKI rule of five to obtain 131 c...
The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response [0.03%]
针对SARS-CoV2的生物制剂的研发：抗体在免疫反应较差的患者群体中的治疗潜力
William Migo,Marko Boskovic,Robert Likic
William Migo
Development of novel antibodies to combat the novel SARS-CoV-2 virus is ongoing. Importantly, particular subgroups are more prone to severe disease, namely patients with poor immune responses. This includes cancer patients with solid and ha...
An updated review on potential therapeutic drug candidates, vaccines and an insight on patents filed for COVID-19 [0.03%]
针对COVID-19潜在的治疗药物和疫苗候选者最新评论及对已申请专利的一些见解
G S N Koteswara Rao,Buduru Gowthami,N Raghavendra Naveen et al.
G S N Koteswara Rao et al.
The outbreak of COVID-19 was recognized in December 2019 in China and as of October5th, the pandemic was swept through 216 countries and infected around 34,824,108 individuals, thus posing an unprecedented threat to world's health and econo...
Can the application of graphene oxide contribute to the fight against COVID-19? Antiviral activity, diagnosis and prevention [0.03%]
氧化石墨烯在抗击COVID-19中能发挥什么作用？抗病毒活性、诊断和预防
Asmaa Rhazouani,Khalid Aziz,Halima Gamrani et al.
Asmaa Rhazouani et al.
COVID-19 is an infectious disease that affects the respiratory system and is caused by the novel coronavirus SARS-CoV-2. It was first reported in Wuhan, China, on December 31, 2019, and has affected the entire world. This pandemic has cause...
Devavrat Tripathi,Megha Sodani,Pramod Kumar Gupta et al.
Devavrat Tripathi et al.
The global spread of SARS-CoV-2 has necessitated the development of novel, safe and effective therapeutic agents against this virus to stop the pandemic, however the development of novel antivirals may take years, hence, the best alternativ...
Recent progress in the development of potential drugs against SARS-CoV-2 [0.03%]
对抗SARS-CoV-2潜在药物研发的近期进展
Jianmin Chen,Fayaz Ali,Imran Khan et al.
Jianmin Chen et al.
SARS-CoV-2, a newly emerged and highly pathogenic coronavirus, is identified as the causal agent of Coronavirus Disease (2019) (COVID-19) in the late December 2019, in China. The virus has rapidly spread nationwide and spilled over to the o...